Table 1.
Baseline clinical characteristics of the population for efficacy analysis.
| All (n = 41) | ||
|---|---|---|
| Age, years | 62 | (51, 73) |
| Male sex, n (%) | 22 | (54) |
| BMI, kg/m2 | 25.2 | (20.8, 29.7) |
| Body temperature, °C | 38.0 | (37.5, 38.5) |
| Complications | ||
| Hypertension, n (%) | 19 | (46) |
| Dyslipidemia, n (%) | 13 | (32) |
| Diabetes, n (%) | 10 | (24) |
| CKD, n (%) | 10 | (24) |
| Antipyretic drug, n (%) | 29 | (70) |
| Ciclesonide, n (%) | 14 | (34) |
| Oxygen administration, n (%) | 7 | (17) |
Data are presented as median (interquartile range [IQR]: 25th to 75th percentile) or numbers (with percentages). P < 0.05 was considered statistically significant. Abbreviations: BMI, body mass index; CKD, chronic kidney disease.